Exposure-response methods and dose approval of new oncology drugs by FDA from 2005 to 2015.

被引：4
|
作者：
Minchella, Kaitlyn [1 ]
Xu, Hongmei [1 ]
Al-Huniti, Nidal [1 ]
机构：
[1] AstraZeneca, Waltham, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.2530
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2530
引用
收藏
页数：2
相关论文
共 36 条
  • [1] Survey of Methodologies for Exposure-Response Analysis of Oncology Drugs Approved in FDA from 2010 to 2015
    Lu, Tong
    Lu, Dan
    Lum, Bert L.
    Stroh, Mark
    Agarwal, Priya
    Jin, Jin Y.
    Joshi, Amita
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S91 - S91
  • [2] Review and Approval of Oncology and Hematology Drugs at FDA from 2005 to 2007
    不详
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (04)
  • [3] 2015 in review: FDA approval of new drugs
    Kinch, Michael S.
    [J]. DRUG DISCOVERY TODAY, 2016, 21 (07) : 1046 - 1050
  • [4] Esomeprazole FDA Approval in Children With GERD: Exposure-Matching and Exposure-Response
    Earp, Justin C.
    Mehrotra, Nitin
    Peters, Kristina E.
    Fiorentino, Robert P.
    Griebel, Donna
    Lee, Sue C.
    Mulberg, Andrew
    Rohss, Kerstin
    Sandstrom, Marie
    Taylor, Amy
    Tornoe, Christoffer W.
    Wynn, Erica L.
    Van der Walt, Jan-Stefan
    Garnett, Christine
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2017, 65 (03): : 272 - 277
  • [5] The impact of modelling and simulation in oncology: a survey of all drugs approved in oncology by the FDA 2005-2015.
    Edlund, Helena
    Lin, Tylee
    Minchella, Kaitlyn
    Xu, Hongmei
    Penland, Robert C.
    Masson, Eric
    Al-Huniti, Nidal
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S55 - S55
  • [6] LEARNINGS FROM FDA CLINICAL PHARMACOLOGY (CP) REVIEWS OF ONCOLOGY (ONC) NEW MOLECULAR ENTITIES (NMES) APPROVED FROM 2011 TO 2015.
    Faucette, S.
    Trivedi, A.
    Gupta, N.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S93 - S93
  • [7] United States Stock Market Response to FDA Approval of New Dermatologic Drugs
    Mazmudar, Rishabh S.
    Tripathi, Raghav
    Ezaldein, Harib H.
    Scott, Jeffrey E.
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (06) : 639 - 645
  • [8] EXPOSURE-RESPONSE MODELING STRATEGIES IN ONCOLOGY: IMPACT OF DOSE REDUCTIONS ON INTERPRETATION OF RESULTS.
    Yue, M.
    Lombard, A.
    Pitou, C.
    Chigutsa, E.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S35 - S35
  • [9] Applying interpretable machine learning workflow to evaluate exposure-response relationships for large-molecule oncology drugs
    Liu, Gengbo
    Lu, James
    Lim, Hong Seo
    Jin, Jin Yan
    Lu, Dan
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (12): : 1614 - 1627
  • [10] The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs
    Sekaggya-Wiltshire, Christine
    Lamorde, Mohammed
    Kiragga, Agnes N.
    Dooley, Kelly E.
    Kamya, Moses R.
    Kambugu, Andrew
    Fehr, Jan
    Manabe, Yukari C.
    Castelnuovo, Barbara
    [J]. TUBERCULOSIS, 2018, 108 : 77 - 82
1234